PFCS
KZR

Pale Fire Capital SE’s Kezar Life Sciences KZR Stock Holding History

Pale Fire Capital SE’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,885
Closed -$65.2K – 67
2023
Q4 		$65.2K Hold
6,885
– – 0.01% 68
2023
Q3 		$81.9K Buy
+6,885
New +$122K 0.01% 60

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pale Fire Capital SE's KZR Position: Q1 2024 in Review

Pale Fire Capital SE sold out of Kezar Life Sciences (KZR) in Q1 2024, closing a stake of 6,885 shares — an estimated $65.2K sold.

Pale Fire Capital SE first reported a position in KZR in Q3 2023 and held it in 2 quarters. The position peaked at $81.9K in Q3 2023. 85 funds tracked by Wall St. Rank hold KZR as of Q1 2024.

  • Pale Fire Capital SE reported no remaining Kezar Life Sciences position as of Q1 2024 after selling out during the quarter.
  • Pale Fire Capital SE sold 6,885 Kezar Life Sciences shares in Q1 2024, an estimated $65.2K.
  • Pale Fire Capital SE first reported a position in Kezar Life Sciences in Q3 2023 and held it in 2 quarters.
  • Pale Fire Capital SE's Kezar Life Sciences position peaked at $81.9K in Q3 2023.
  • 85 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2024.

Based on Pale Fire Capital SE's 13F filing for Q1 2024, filed 14 May 2024.